Copper(I) Complexes Antitumor Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platinum-based anticancer drugs face limitations due to severe toxic effects on normal tissues and the development of resistance, necessitating the exploration of alternative metal-based compounds with improved pharmacological profiles.
Innovation Solution
Development of Cu(I) complexes with specific aromatic/heteroaromatic ligands that exhibit enhanced antitumor activity compared to existing agents like oxaliplatin and cisplatin, demonstrating higher cytotoxicity and selectivity towards cancer cells while minimizing toxicity to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based drugs (cisplatin, carboplatin, oxaliplatin) are used to treat cancer, then antitumor efficacy is improved, but severe toxic effects on normal tissues and resistance phenomena worsen
Solution Approach 1:
The patent changes the metal center parameter from platinum to copper, specifically using Cu(I) instead of Pt(II/IV). This fundamental parameter change allows the complex to maintain antitumor activity through a different mechanism while avoiding the severe toxicity and resistance issues associated with platinum-based drugs
Solution Approach 2:
The patent introduces copper as an intermediary metal that can achieve similar therapeutic effects to platinum but through different biological pathways. The Cu(I) complex acts as a mediator that exploits copper's natural biological cycles and cellular uptake mechanisms to deliver antitumor activity with reduced off-target toxicity
2Reliability
If platinum-based drugs are used to treat cancer, then antitumor efficacy is improved, but resistance phenomena worsen
Solution Approach 1:
By changing the metal center from platinum to copper, the patent creates a compound that acts through different molecular mechanisms, thereby bypassing resistance pathways developed against platinum drugs. The Cu(I) complex engages different cellular targets and signaling pathways that are not affected by platinum resistance mechanisms
Solution Approach 2:
Instead of trying to overcome platinum resistance by modifying platinum compounds, the patent inverts the approach by completely switching to a different metal (copper) that naturally circumvents platinum-based resistance mechanisms. This inversion strategy allows treatment of tumors that have developed resistance to conventional platinum therapy
3Object-affected harmful factors
If non-platinum metal complexes are developed to treat cancer, then toxicity to normal cells is reduced, but antitumor activity may be compromised
Solution Approach 1:
The patent optimizes the copper complex parameters by selecting Cu(I) oxidation state and specific ligand combinations (L1-L14) to achieve the right balance between toxicity reduction and activity maintenance. The parametric optimization of the coordination sphere ensures high antitumor potency while leveraging copper's favorable safety profile
Solution Approach 2:
The patent creates composite copper complexes combining Cu(I) center with specially designed organic ligands (L1-L14). These composite structures integrate the low toxicity of copper with the targeted antitumor activity of the ligand system, achieving both reduced normal cell toxicity and maintained or enhanced anticancer efficacy
4Reliability
If Cu(I) complexes with aromatic/heteroaromatic ligands are used, then cytotoxic activity is improved, but selectivity towards cancer cells must be maintained
Solution Approach 1:
The patent changes the ligand parameters to include aromatic and heteroaromatic structures (L1-L14) that enhance the complex's ability to interact with cancer cell targets. These ligand modifications increase cytotoxic activity while the inherent copper biology maintains selectivity
Solution Approach 2:
The patent exploits the self-service mechanism of copper biology where endogenous copper transporters (CTR1) and cellular copper metabolism pathways automatically provide selective uptake and activation of the Cu(I) complex in cancer cells. The system uses the cell's own copper handling machinery to achieve selective delivery and activation, reducing the need for additional targeting groups
Data Source
AI summary
The invention relates to a Cu(1) complex of Formula (I), wherein L is a ligand of Formula (II), wherein n1, n2, n3 are independently to each other, an integer from 0 to 1, A1, A2 and A3 are independently from each other,—a phenyl optionally substituted with (C1-C3)alkoxy, (C1-C3)alkyl, F, formyl, carboxyl, sulphonyl hydroxyl, hydroxyl, methoxy(C1-C3)alkoxy or—an heterocyclic ring selected from piperazinyl, morpholynyl, thiomorpholynyl, optionally substituted with (C1-C3)alkyl, where the heterocyclic ring is linked with the nitrogen atom to —CH2— residue, with the proviso that when A1, A2 or A3 is optionally substituted phenyl, then n1, n2 or n3, respectively, is 0, and when A1, A2 or A3 is optionally substituted heterocyclic ring, then n1, n2 or n3, respectively, is 1, for use in the treatment of tumours.